Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced five presentations at the 15th Annual World ADC Conference in San Diego, November 4-6, 2024. The presentations cover various aspects of ADC innovation, including: dual-payload ADCs development, clinical updates on Luvelta targeting folate receptor, preclinical development of STRO-004, cell-free protein synthesis for site-specific conjugation, and optimization of high DAR and dual payload ADCs. The presentations will be available on Sutro's website after the event.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations at the 15th Annual World ADC Conference, taking place in San Diego, November 4-6, 2024.

Presentation Details:

• Development of Dual-Payload Antibody Drug Conjugates 
  • Presenter: Daniel Calarese, Ph.D.
  • Date/Time: November 4, 2024, 2:00pm PT
    
    
• Showcasing Clinical Update & Learnings for Luvelta Targeting Folate Receptor
  
  
  • Presenter: Hanspeter Gerber, Ph.D.
  • Date/Time: November 5, 2024, 11:30am PT
    
    
• Characterizing ADC Safety & Activity in Preclinical Development of STRO-004 
  
  
  • Presenter: Alice Yam, Ph.D.
  • Date/Time: November 5, 2024, 2:00pm PT 
    
    
• Leveraging Cell-Free Protein Synthesis for Site- Specific Conjugation to Enhance ADC Therapeutic Index 
  
  
  • Presenter: Gang Yin, Ph.D.
  • Date/Time: November 5, 2024, 2:30pm PT
    
    
• Optimizing High DAR & Dual Payload ADCs: Discovery of Hydrophilic β-glu Cleavable Linker Payloads for Superior Efficacy and Safety 
  
  
  • Presenter: Krishna Bajjuri, Ph.D.
  • Date/Time: November 6, 2024, 3:00pm PT
    

Following the event, the content will be made available in the Clinical/Scientific Presentation and Publication Highlights section of Sutro Biopharma’s website at www.sutrobio.com.

About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF^®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

FAQ

What presentations will Sutro Biopharma (STRO) give at the 2024 World ADC Conference?

Sutro Biopharma will present five topics: dual-payload ADCs development, Luvelta clinical updates, STRO-004 preclinical development, cell-free protein synthesis for conjugation, and optimization of high DAR and dual payload ADCs.

When and where is Sutro Biopharma (STRO) presenting at the World ADC Conference 2024?

Sutro Biopharma is presenting at the 15th Annual World ADC Conference in San Diego from November 4-6, 2024, with presentations scheduled throughout the three days.

What will be presented about STRO-004 at the 2024 World ADC Conference?

Dr. Alice Yam will present on characterizing ADC safety and activity in the preclinical development of STRO-004 on November 5, 2024, at 2:00pm PT.